Paragon Board Responds to Gad's Latest Misleading Statements - Shareholders Deserve the Truth
Gad Continues Pattern of Lying to Shareholders and Misrepresenting the Facts
EASTON, PA / ACCESS Newswire / May 20, 2025 / Paragon Technologies' (OTCPK:PGNT) ('Paragon' or the 'Company') today responded to former Chairman and CEO Hesham 'Sham' Gad's latest attempt to rewrite history, calling out his deliberate misinformation and ongoing efforts to mislead shareholders.
There's a reason Mr. Gad is no longer Chairman or CEO of the Company: his actions made him unfit to lead.
Gad's assertion regarding 'false, damaging, and despicable statements' concerning the hiring of unauthorized workers is a blatant misrepresentation. The singular instance of an unauthorized hire involved Mr. Gad himself, who knowingly resided and worked illegally in the United States for over two decades. His failure to disclose this critical information not only betrayed Paragon's trust - it exposed the Company to significant legal and reputational risk.
Gad's baseless accusations against Directors Eriksen, Brownstein, Lontini, and Weiser are directly contradicted by the facts. The legal counterclaim against Gad, accessible at link to counterclaim, provides a comprehensive account of Mr. Gad's extensive history of dishonesty, alleged theft, and repeated breaches of fiduciary duty.
Additionally, Mr. Gad prolonged the litigation long after the bylaws he sought to have repealed were, in fact, repealed, potentially costing shareholders millions. His ongoing litigation included accusations against the new independent directors related to their adoption of the shareholder's rights plan. The independent directors believe they were adhering to their fiduciary duties in adopting the rights plan and were advised that Delaware case law suggests that it could be a breach of fiduciary duty for them NOT to adopt the plan in light of the threat of creeping control posed by the 40 percent plus shareholder group. Yet Gad sued, derived no benefit other than for himself at shareholder expense.
Gad's allegations of concealment regarding the recent litigation are even more unfounded. Gad was involved in the board discussions including the reasons for filing under seal. The current board has nothing to hide from shareholders. Shareholders wishing to obtain a copy of the complaint filed against the company's former corporate counsel can do so by making the request at [email protected]. What Mr. Gad fails to disclose to shareholders is that the litigation demolishes his contrived entrenchment theory against Mr. Weiser and the Board. In fact, in the board's discussions, Gad's only objection was that the facts made him look bad. If the facts make him look bad, so be it.
The Board urges all shareholders to see through Mr. Gad's self-serving rhetoric for what it is: a transparent attempt to divert attention from his own actions and obstruct the current leadership's commitment to transparency and accountability. We encourage shareholders to rely on factual information, including the detailed legal filings that expose Mr. Gad's long-standing pattern of deceit and mismanagement, rather than his continued distortions. The Board remains focused on transparency, accountability, and protecting the long-term interest of Paragon's shareholders.
About Paragon Technologies
Paragon Technologies, Inc. is a holding company owning subsidiaries that engage in diverse business activities, including material handling, distribution, real estate, and investments. For additional information please visit: www.pgntgroup.com.
Investor Relations Contact:
Alliance Advisors IR
[email protected]
SOURCE: Paragon Technologies Inc.
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Maha Radhakrishnan, MD BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. 'We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year,' said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. 'I'm honored to join the Board of Entrada as it advances its clinical-stage portfolio of Duchenne therapies and its growing pipeline of novel approaches for devastating diseases,' said Dr. Radhakrishnan. 'The promising Phase 1 safety and target engagement data, along with the urgent need for new treatments, reinforce the potential of Entrada's approach to change the lives of people living with Duchenne. I look forward to working with Dipal and the Board to help bring this new class of intracellular therapies to patients and families affected by Duchenne and other serious illnesses.' Since August 2024, Dr. Radhakrishnan has served as Executive Partner at Sofinnova Investments, a European venture capital firm focused on life sciences. At Sofinnova Investments, Dr. Radhakrishnan leads in-depth diligence across clinical-ready assets in multiple therapeutic areas and provides expertise to portfolio companies in areas including product development and commercialization. From January 2020 to March 2024, Dr. Radhakrishnan served as Group Senior Vice President and Chief Medical Officer at Biogen (NASDAQ: BIIB) where she was responsible for the worldwide medical function. Prior to Biogen, she served as Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi. Previously, she held several leadership roles at Bioverativ (acquired by Sanofi), Bristol Myers Squibb, UnitedHealth Group and Cephalon (acquired by Teva Pharmaceuticals). Dr. Radhakrishnan received her M.D. in Internal Medicine with honors from the People's Friendship University in Moscow, Russia, as well as a Master's degree in the Russian language. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. For more information about Entrada, please visit our website, and follow us on LinkedIn. Forward-Looking StatementsThis press release contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada's strategy, future operations, prospects and plans, objectives of management, the validation and differentiation of Entrada's approach and EEV platform and its ability to provide a potential treatment for patients, and expectations regarding global Phase 2 clinical studies for ENTR-601-44, ENTR-601-45 and ENTR-601-50, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'predict,' 'project,' 'potential,' 'should,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties identified in Entrada's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-K and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this press release represent Entrada's views as of the date of this press release. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada's views as of any date subsequent to the date of this press release. Investor ContactKarla MacDonaldChief Corporate Affairs Officerkmacdonald@ Media ContactMegan Prock McGrathCTD Comms, LLCmegan@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
42 minutes ago
- Associated Press
Chromalloy Announces Appointment of Paul Browning to Board of Directors
PALM BEACH GARDENS, FLORIDA / ACCESS Newswire / June 3, 2025 / Chromalloy is a global leader for turbine engine aftermarket solutions, that include providing engineering, part manufacturing, component repairs, and full powerplant restoration to serve the aviation, defense, and energy markets. Chromalloy has announced the appointment of Paul Browning to its Board of Directors. Paul has spent 35 years as an executive leader and entrepreneur, with a focus on driving innovation and growth for multi-national businesses in the power generation market. 'We are pleased to welcome Paul Browning to the Chromalloy Board,' said Chris Celtruda, Chief Executive Officer for Chromalloy. 'Paul has deep knowledge and long-term relationships in the global power generation market and a mindset for driving strategic growth. His leadership and experience will be instrumental as we continue to expand the Chromalloy solution set for the rapidly growing distributed power market.' On joining the Chromalloy board, Browning commented, 'I worked with Chromalloy extensively during my career and have always respected their legacy of disruptive technology development for turbine engine overhaul. I'm proud to join the Board at this pivotal time in the company's history and am committed to helping position Chromalloy as both a high-value alternative and a trusted partner within OEM-aligned solutions for land-based turbines.' Paul has served in senior leadership and CEO roles at numerous multinational corporations, including Caterpillar Solar Turbines, GE Power, Irving Oil, and Mitsubishi Power. More recently he has been engaged in advisory roles for traditional power and transitional energy businesses. Mr. Browning is a lifelong learner, with a strong commitment to technological development, innovation, and maintaining industry relationships that are critical to establishing a growth roadmap. He holds a B.S. in Metallurgical Engineering and Materials Science from Carnegie Mellon University and an M.S. in Materials Engineering from Rensselaer Polytechnic Institute. In May of 2025, Paul completed a 27-year journey, interrupted by a growing family and an executive career, that culminated in the completion of a Ph.D. in Materials Engineering from Rensselaer Polytechnic Institute. About Chromalloy Chromalloy is a leading provider of engineering, manufacturing, and service for the aerospace, military, aero-derivative, and energy/industrial gas turbine aftermarket. For over 70 years, Chromalloy has been a trusted partner of airlines, aero-engine asset owners, and engine repair facilities. Chromalloy is a leader in FAA-certified, third-party PMA and DER solutions to enable customer value during engine restoration and maintenance. The combination of alternative PMA new parts, DER part repairs, and inventory of used serviceable material (USM) enables each engine overhaul to achieve expected performance and achieve best value. Operating from over 20 locations worldwide, Chromalloy remains committed to having the right global team, available inventory, and a bias for addressing service needs for legacy and midlife engines. Our investments in design engineering, testing, and component manufacturing ensure that all regulatory and performance criteria are met or exceeded. As of May 2025, Chromalloy has developed and received FAA approval on over 50 gas path PMA parts, which have safely flown in excess of 6 BILLION flight hours with ZERO airworthiness directives. Chromalloy's PMA parts are certified by the FAA to be equivalent to the original equipment manufacturer (OEM) part and meet all requirements. For additional information, please visit Contact Information Chromalloy Marketing [email protected] 561.935.3571 SOURCE: Chromalloy press release
Yahoo
an hour ago
- Yahoo
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
- Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine ("DMT") and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 - - Cybin's growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications - TORONTO, June 03, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder ("GAD"). The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ("IM") injection, including CYB004. "Patents are extremely valuable assets, and protection for our lead product candidates is a top priority for us," said Doug Drysdale, Chief Executive Officer of Cybin. "We believe that our CYB004 program has the potential to deliver short-duration, rapid-acting treatment for anxiety disorders and offer more patient-friendly dosing methods such as IM administration. The issuance of this additional patent in support of CYB004 adds further validation of this important program. Dosing is currently underway in our Phase 2 study evaluating CYB004 in generalized anxiety disorder, and we expect the study to complete around mid-year. I'm proud that Cybin has amassed one of the strongest IP portfolios in the sector with more than 90 granted patents and over 230 pending applications." About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's expectations respecting the patent exclusivity period; plans to complete the Phase 2 GAD study around mid-year 2025; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. View source version on Contacts Investor & Media Contact: Gabriel FahelChief Legal OfficerCybin Inc.1-866-292-4601irteam@ – or – media@ Sign in to access your portfolio
